These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

633 related items for PubMed ID: 18310788

  • 1. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T, Turan S, Guran T, Bereket A.
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [Abstract] [Full Text] [Related]

  • 2. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C, Rauch F, Travers R, Glorieux FH.
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [Abstract] [Full Text] [Related]

  • 3. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
    Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C.
    Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
    DiMeglio LA, Peacock M.
    J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
    [Abstract] [Full Text] [Related]

  • 6. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS, Glorieux FH, Rauch F.
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B, Aström E, Söderhäll S.
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
    Shah I, Johari A.
    Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
    [Abstract] [Full Text] [Related]

  • 18. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
    Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M.
    Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.